Welcome to our dedicated page for Trendlines news (Ticker: TRNGF), a resource for investors and traders seeking the latest updates and insights on Trendlines stock.
The Trendlines Group Ltd. (TRNGF) is associated with The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), which appears in multiple portfolio company announcements as an investment group focused on early-stage medical technology and life sciences ventures. News related to The Trendlines Group often comes through updates from its portfolio companies, providing insight into the progress of medical device and healthcare technology innovations that Trendlines supports.
Investors and observers following TRNGF can use this news feed to monitor milestones achieved by portfolio companies that cite The Trendlines Group as an investor or incubator. Recent announcements include funding rounds, regulatory clearances, and clinical achievements by companies such as Escala Medical Ltd., Arcuro Medical Ltd., Limaca Medical Ltd., Vensica Medical, ZygoFix Ltd., Fidmi Medical Ltd., Vessi Medical, Dasyo, and Ceretrieve, all of which reference The Trendlines Group in their disclosures.
Typical news items include FDA clearances for new medical devices, clinical study results in areas such as ischemic stroke and bladder cancer, funding rounds to advance commercialization or clinical trials, and strategic appointments at portfolio companies. These developments highlight the types of innovations and regulatory milestones that can influence the value and outlook of an investment group focused on MedTech and life sciences.
By reviewing this page regularly, users can track how The Trendlines Group’s portfolio evolves over time through public announcements from its investee companies, gaining a clearer picture of the themes, technologies, and therapeutic areas that shape the company’s exposure within the healthcare and medical technology landscape.
Vessi Medical has completed its first-in-human procedure using its cryoablation solution for non-muscle invasive bladder cancer (NMIBC) at Rambam Healthcare Campus, Israel. The procedure was successful, demonstrating ease of use and no complications, with the patient reporting no pain post-discharge. This marks a significant step towards regulatory approval for Vessi's minimally invasive treatment, which aims to improve patient quality of life compared to traditional surgical options.
ZygoFix has received the CE mark for its innovative zLOCK Spinal Fusion System designed for chronic back pain treatment. This minimally invasive system utilizes a screwless design, enhancing safety and reducing surgical invasiveness with only two incisions needed compared to traditional methods. The zLOCK system has been in clinical use in Hungary and Israel for over three years, demonstrating high satisfaction among patients and physicians. ZygoFix also secured ISO13485 certification and plans to conduct a pivotal study in the EU to gather more clinical data.
Omeq Medical has appointed Carl Rickenbaugh as the chair of its board of directors. Rickenbaugh, with extensive experience in the medical device sector, aims to lead Omeq's strategic direction toward commercialization of its innovative epidural delivery technology. The company’s device enhances the accuracy of epidural injections, a procedure used in over 40 million cases annually, addressing complications from misplacement that affect up to 30% of procedures. Omeq is a portfolio company of The Trendlines Group Ltd., supported by grants from the Israeli Innovation Authority.